Selank/Semax Nasal Spray 60mg

The Selank/Semax Nasal Spray is a combined formulation of two synthetic heptapeptides — Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) and Semax (Met-Glu-His-Phe-Pro-Gly-Pro) — both developed at the Institute of Molecular Genetics of the Russian Academy of Sciences in the 1980s–1990s, both extensively researched in intranasal delivery formulations. This combined nasal-spray product packages 60mg of total peptide content (combining both components) in a delivery format that matches the original Russian research literature, where intranasal administration was the dominant route used in pharmacological studies. Each component peptide also exists as a separate single-molecule product in our catalog with its own dedicated research guide; this guide focuses specifically on the combined nasal-spray formulation.

The product combines Selank and Semax into a single intranasal-delivery formulation. Both component peptides are seven-residue synthetic sequences engineered with a common C-terminal Pro-Gly-Pro tail (added to slow enzymatic degradation) but derived from different parent molecules — Selank from tuftsin and Semax from the N-terminal fragment of ACTH(4-10). The 60mg figure represents combined peptide content; per-component breakdown and the formulation ratio are documented on each batch's Certificate of Analysis. The product is supplied as an aqueous nasal-spray formulation in a delivery vial appropriate for intranasal research use.

Selank/Semax Nasal Spray is sold strictly for laboratory and research use. It is not approved by the FDA or any other regulatory body for human or veterinary use, and nothing in this guide constitutes guidance for human administration.

The Russian research literature that established both Selank and Semax's neuromodulation profiles predominantly used intranasal administration. The choice was driven by two factors: small heptapeptides cross the nasal mucosa effectively, and the olfactory and trigeminal nerve pathways from the nasal cavity provide a relatively direct route to central-nervous-system tissues — bypassing the systemic circulation that limits brain exposure for many other peptides. Researchers replicating or extending the original Russian work in mammalian models often choose intranasal delivery specifically because it matches the route used in the foundational literature; the combined Selank/Semax nasal spray supports that protocol design directly.

Every batch of MHS Longevity Selank/Semax Nasal Spray is submitted to an independent third-party laboratory before release. The combined formulation requires component-by-component verification plus liquid-formulation testing:

Selank/Semax Nasal Spray as a sterile liquid formulation should be stored refrigerated (2–8°C) for the sealed vial, with the documented sealed-vial shelf life printed on the label. After first access, an in-use stability window applies — the components are stable in aqueous solution but degrade faster than in lyophilized form, so single-vial-per-experimental-arm use is good practice for protocols requiring strict ratio consistency. Protect from light during storage. Standard aseptic technique applies during use.